Clinical trials of several ICIs that target PD-L1, CTLA-4, TIGIT, IDO1, TIM-3, LAG-3, and VISTA are currently underway for advanced solid cancers, including CRC (48). Here, HAVCR2 is linked to colorectal carcinoma.